The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide

Chunkyu Ko, Woo Jin Park, Sanghyun Park, Seungtaek Kim, Marc P. Windisch, Wang Shick Ryu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Little is known about the early steps of the HBV life cycle due to the lack of susceptible cells permissive for viral infection. Hence, viral entry has not been exploited for antiviral targets, but the recent seminal discovery of sodium taurocholate co-transporting polypeptide (NTCP) as the cellular receptor for HBV entry opened up many avenues of investigation, making HBV entry amenable to therapeutic intervention. Methods: In order to exploit HBV entry, we established a HepG2-NTCP cell line that supports HBV infection. Over 70% of cells were infected at a dose of 104 genome equivalents (GEq) per cell. Several FDA-approved drugs with NTCP-inhibiting activity were tested for their ability to inhibit HBV infection of the cell line. Results: Consistent with their NTCP inhibitory activities, our results showed that several of them inhibit HBV infection. In particular, irbesartan, a drug used for the treatment of hypertension, inhibits HBV infection at the 50% effective concentration value of 35 μM. Conclusions: The observation that the pharmacological inhibitors of the NTCP transporter could block HBV entry suggests that NTCP represents an attractive molecular target for therapeutic intervention in HBV infection.

Original languageEnglish
Pages (from-to)835-842
Number of pages8
JournalAntiviral Therapy
Volume20
Issue number8
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

irbesartan
Taurocholic Acid
Hep G2 Cells
Peptides
Infection
Pharmaceutical Preparations
Cell Line
Virus Diseases
Life Cycle Stages
Antiviral Agents
Genome
Pharmacology
Hypertension

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Ko, Chunkyu ; Park, Woo Jin ; Park, Sanghyun ; Kim, Seungtaek ; Windisch, Marc P. ; Ryu, Wang Shick. / The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. In: Antiviral Therapy. 2015 ; Vol. 20, No. 8. pp. 835-842.
@article{98589543ef9d44efbf8779fefc7aac87,
title = "The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide",
abstract = "Background: Little is known about the early steps of the HBV life cycle due to the lack of susceptible cells permissive for viral infection. Hence, viral entry has not been exploited for antiviral targets, but the recent seminal discovery of sodium taurocholate co-transporting polypeptide (NTCP) as the cellular receptor for HBV entry opened up many avenues of investigation, making HBV entry amenable to therapeutic intervention. Methods: In order to exploit HBV entry, we established a HepG2-NTCP cell line that supports HBV infection. Over 70{\%} of cells were infected at a dose of 104 genome equivalents (GEq) per cell. Several FDA-approved drugs with NTCP-inhibiting activity were tested for their ability to inhibit HBV infection of the cell line. Results: Consistent with their NTCP inhibitory activities, our results showed that several of them inhibit HBV infection. In particular, irbesartan, a drug used for the treatment of hypertension, inhibits HBV infection at the 50{\%} effective concentration value of 35 μM. Conclusions: The observation that the pharmacological inhibitors of the NTCP transporter could block HBV entry suggests that NTCP represents an attractive molecular target for therapeutic intervention in HBV infection.",
author = "Chunkyu Ko and Park, {Woo Jin} and Sanghyun Park and Seungtaek Kim and Windisch, {Marc P.} and Ryu, {Wang Shick}",
year = "2015",
month = "1",
day = "1",
doi = "10.3851/IMP2965",
language = "English",
volume = "20",
pages = "835--842",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "8",

}

The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. / Ko, Chunkyu; Park, Woo Jin; Park, Sanghyun; Kim, Seungtaek; Windisch, Marc P.; Ryu, Wang Shick.

In: Antiviral Therapy, Vol. 20, No. 8, 01.01.2015, p. 835-842.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide

AU - Ko, Chunkyu

AU - Park, Woo Jin

AU - Park, Sanghyun

AU - Kim, Seungtaek

AU - Windisch, Marc P.

AU - Ryu, Wang Shick

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Little is known about the early steps of the HBV life cycle due to the lack of susceptible cells permissive for viral infection. Hence, viral entry has not been exploited for antiviral targets, but the recent seminal discovery of sodium taurocholate co-transporting polypeptide (NTCP) as the cellular receptor for HBV entry opened up many avenues of investigation, making HBV entry amenable to therapeutic intervention. Methods: In order to exploit HBV entry, we established a HepG2-NTCP cell line that supports HBV infection. Over 70% of cells were infected at a dose of 104 genome equivalents (GEq) per cell. Several FDA-approved drugs with NTCP-inhibiting activity were tested for their ability to inhibit HBV infection of the cell line. Results: Consistent with their NTCP inhibitory activities, our results showed that several of them inhibit HBV infection. In particular, irbesartan, a drug used for the treatment of hypertension, inhibits HBV infection at the 50% effective concentration value of 35 μM. Conclusions: The observation that the pharmacological inhibitors of the NTCP transporter could block HBV entry suggests that NTCP represents an attractive molecular target for therapeutic intervention in HBV infection.

AB - Background: Little is known about the early steps of the HBV life cycle due to the lack of susceptible cells permissive for viral infection. Hence, viral entry has not been exploited for antiviral targets, but the recent seminal discovery of sodium taurocholate co-transporting polypeptide (NTCP) as the cellular receptor for HBV entry opened up many avenues of investigation, making HBV entry amenable to therapeutic intervention. Methods: In order to exploit HBV entry, we established a HepG2-NTCP cell line that supports HBV infection. Over 70% of cells were infected at a dose of 104 genome equivalents (GEq) per cell. Several FDA-approved drugs with NTCP-inhibiting activity were tested for their ability to inhibit HBV infection of the cell line. Results: Consistent with their NTCP inhibitory activities, our results showed that several of them inhibit HBV infection. In particular, irbesartan, a drug used for the treatment of hypertension, inhibits HBV infection at the 50% effective concentration value of 35 μM. Conclusions: The observation that the pharmacological inhibitors of the NTCP transporter could block HBV entry suggests that NTCP represents an attractive molecular target for therapeutic intervention in HBV infection.

UR - http://www.scopus.com/inward/record.url?scp=84975139885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975139885&partnerID=8YFLogxK

U2 - 10.3851/IMP2965

DO - 10.3851/IMP2965

M3 - Article

VL - 20

SP - 835

EP - 842

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 8

ER -